Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (US20170308657) Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

Claims

1. A method for at least one of characterizing, diagnosing, and treating an autoimmune condition of a subject, the method comprising:
providing sampling kits to a population of subjects at remote locations, each sampling kit including a sample container having a pre-process reagent component;
receiving an aggregate set of samples from the sampling kits of the population of subjects;
with a next generation sequencing platform of a sample processing system, generating sequence datasets upon sequencing nucleic acid content of microorganism portions of the aggregate set of samples;
generating a microbiome feature dataset for the population of subjects based upon the sequence datasets for the population of subjects;
generating a characterization model of the autoimmune condition from features extracted from the microbiome feature dataset and a supplementary dataset informative of characteristics associated with the autoimmune condition;
characterizing the subject with the autoimmune condition upon processing a sample from the subject according to the characterization model; and
at an output device associated with the subject, providing a therapy to the subject with the autoimmune condition.
2. The method of claim 1, wherein generating sequence datasets from the population of subjects further comprises: identifying primers for nucleic acid sequences associated with the autoimmune condition, fragmenting nucleic acid material of the aggregate set of samples, amplifying the fragmented nucleic acid material using the identified primers, and determining alignments to reference sequences associated with the autoimmune condition.
3. The method of claim 1, wherein identifying primers comprises selecting at least one primer with a synthetic identifier sequence, for multiplex amplification.
4. The method of claim 1, wherein the sample processing system comprises amplification substrates comprising at least one of bridge amplification substrates associated with the next generation sequencing platform and moiety-bound particles.
5. The method of claim 1, further comprising extracting candidate features associated with a set of functional aspects of microbiome components of the microbiome feature dataset; and
characterizing the autoimmune condition in association with a subset of the set of functional aspects, the subset derived from at least one of clusters of orthologous groups of proteins features, genomic functional features from the Kyoto Encyclopedia of Genes and Genomes (KEGG), chemical functional features, and systemic functional features.
6. The method of claim 1, wherein generating the characterization model comprises analyzing a set of features from the microbiome feature dataset with a statistical analysis, wherein the set of features includes features associated with: relative abundance of different taxonomic groups represented in the microbiome feature dataset, ratio between at least two features comprising taxonomic groups and functional features, interactions between different taxonomic groups represented in the microbiome feature dataset, and phylogenetic distance between taxonomic groups represented in the microbiome feature dataset.
7. The method of claim 1, wherein generating the characterization model of the autoimmune condition comprises generating a characterization that is diagnostic of at least one of acquired immune deficiency syndrome (AIDS), multiple sclerosis (MS), asthma, and Sprue.
8. The method of claim 1, wherein generating the characterization model of the autoimmune condition comprises generating a characterization that is diagnostic of at least one of rheumatoid arthritis, Sjogren's syndrome, Type I diabetes, and systemic lupus erythematosus.
9. The method of claim 1, wherein providing the therapy comprises providing instructions to the subject regarding setup of a user account within a patient portal configured to provide microbiome-derived insights to the subject, and transmitting health information pertaining to the autoimmune condition to the subject.
10. The method of claim 1, wherein providing the therapy comprises providing a consumable to the subject, the consumable affecting a microorganism component that selectively modulates microbiome function of the subject, in association with correction of the autoimmune condition.
11. A method for at least one of characterizing, diagnosing, and treating an autoimmune condition of a subject, the method comprising:
providing a sampling kit to the subject at a remote location, the sampling kit including a sample container having a pre-process reagent component and configured to receive a sample from a collection site of the subject;
receiving the sample from the subject;
with a next generation sequencing platform of a sample processing system, generating a microbiome feature dataset upon sequencing nucleic acid content of a microorganism portion of the sample;
generating a characterization of the subject upon processing the microbiome feature dataset with a characterization model derived from a population of subjects having the autoimmune condition;
processing the characterization with a therapy model that determines a therapy for improving a state of the autoimmune condition; and
at an output device associated with the subject, providing the therapy to the subject with the autoimmune condition.
12. The method of claim 11, wherein generating the microbiome feature dataset further includes: identifying primers for nucleic acid sequences associated with the autoimmune condition, fragmenting nucleic acid material of the sample, and amplifying the fragmented nucleic acid material using the identified primers, wherein the sample processing system comprises an amplification substrate comprising at least one of a bridge amplification substrate associated with the next generation sequencing platform and particles coupled to functional moieties.
13. The method of claim 11, wherein generating the characterization of the subject comprises performing a diagnostic test of at least one of acquired immune deficiency syndrome (AIDS), multiple sclerosis (MS), asthma, Sprue, rheumatoid arthritis, Sjogren's syndrome, Type I diabetes, and systemic lupus erythematosus.
14. The method of claim 13, w Herein performing the diagnostic test of AIDS comprises performing a characterization operation with the microbiome feature dataset of the subject and features derived from a set of functions comprising at least one of: a first functional feature related to neurodegenerative diseases, a second functional feature related to transcription, and a third functional feature related to glycolysis/gluconeogenesis.
15. The method of claim 13, wherein performing the diagnostic test of MS comprises performing a characterization operation with the microbiome feature dataset of the subject and a taxonomic feature associated with Lactococcus (genus).
16. The method of claim 13, wherein performing the diagnostic test of asthma comprises performing a characterization operation with the microbiome feature dataset of the subject and features derived from a set of taxa comprising at least one of: Filifactor (genus), Mycoplasma (genus), Mycoplasmataceae (family), and Mycoplasmatales (order).
17. The method of claim 13, wherein performing the diagnostic test of Sprue comprises performing a characterization operation with the microbiome feature dataset of the subject and features derived from 1) a set of taxa comprising at least one of: Bifidobacterium (genus), Bifidobacteriaceae (family), Bifidobacteriales (order), and Actinobacteria (class); and 2) a set of functions comprising at least one of a first functional feature related to carbohydrate metabolism, a second functional feature related to ribosome biogenesis, and a third functional feature related to peptidoglycan biosynthesis.
18. The method of claim 11, wherein providing the therapy comprises providing a consumable to the subject, the consumable affecting a microorganism component that modulates microbiome function in the subject for improvement of the state of the autoimmune condition, based on the therapy model.
19. The method of claim 18, wherein the consumable comprises at least one of: a prebiotic, a probiotic, a phage-based therapy, and a medication.
20. The method of claim 11, wherein providing the therapy comprises providing instructions to the subject regarding setup of a user account within a patient portal configured to provide microbiome-derived insights to the subject, and transmitting diagnostic information and therapeutic techniques, associated with improving the state of the autoimmune condition, to the subject.